Comparison of labetalol and clonidine in hypertension View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1982-09

AUTHORS

M. Lilja, A. J. Jounela, H. Karppanen

ABSTRACT

The antihypertensive effect of labetalol (L) was compared with that of clonidine (C) in a randomized cross-over study in 17 hypertensive outpatients on bendrofluazide (B). After treatment for two weeks with B(5 mg qd), either L (100 mg tid) or C (0.1 mg tid) was given and their doses were titrated at 2-weekly visits until normotension was achieve, or intolerable side-effects occurred. The treatment with B and L or C was than continued in a cross-over fashion for two 6-week periods, with 3 week diuretic washouts and subsequent dose-titration periods between the treatment periods. At the end of B, the supine blood pressure (BP) was 156/101, and at the end of B + L and B + C it was 136/91 (p less than 0.001) and 137/91 (p less than 0.0001), respectively, pooling the data from both periods. At the end of B the standing BP was 155/115, and at the end of B + L and B + C 134/100 (p less than 0.001) and 139/106 (p less than 0.0001), respectively. The mean daily doses required were L 476 mg and C 0.335 mg. On a weight basis, labetalol had about 1/1400 of the potency of clonidine. 12 patients complained of tiredness and dry mouth on clonidine and 2 patients of unsteadiness on labetalol. Labetalol caused a psoriasiform rash on the hands in one patient and limb weakness in one patient. More... »

PAGES

363-367

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00542319

DOI

http://dx.doi.org/10.1007/bf00542319

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1011315160

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7075640


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clonidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ethanolamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Labetalol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Oulu", 
          "id": "https://www.grid.ac/institutes/grid.10858.34", 
          "name": [
            "Department of Medicine, University of Oulu, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lilja", 
        "givenName": "M.", 
        "id": "sg:person.01200755533.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200755533.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oulu", 
          "id": "https://www.grid.ac/institutes/grid.10858.34", 
          "name": [
            "Department of Medicine, University of Oulu, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jounela", 
        "givenName": "A. J.", 
        "id": "sg:person.063042215.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.063042215.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Helsinki", 
          "id": "https://www.grid.ac/institutes/grid.7737.4", 
          "name": [
            "Department of Pharmacology, University of Helsinki, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Karppanen", 
        "givenName": "H.", 
        "id": "sg:person.01205400765.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205400765.11"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00605626", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003306938", 
          "https://doi.org/10.1007/bf00605626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00605626", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003306938", 
          "https://doi.org/10.1007/bf00605626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.1979.tb05815.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014171583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.1979.tb04771.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037617622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1042/cs040018pa", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043032481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1042/cs040018pa", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043032481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.1971.00310140061005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050280467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0028-1111588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057127115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074688491", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079782555", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5694/j.1326-5377.1978.tb112507.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079782555"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080041281", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080271228", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081648518", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082562598", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082562605", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082562607", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082562614", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083377593", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083377595", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1982-09", 
    "datePublishedReg": "1982-09-01", 
    "description": "The antihypertensive effect of labetalol (L) was compared with that of clonidine (C) in a randomized cross-over study in 17 hypertensive outpatients on bendrofluazide (B). After treatment for two weeks with B(5 mg qd), either L (100 mg tid) or C (0.1 mg tid) was given and their doses were titrated at 2-weekly visits until normotension was achieve, or intolerable side-effects occurred. The treatment with B and L or C was than continued in a cross-over fashion for two 6-week periods, with 3 week diuretic washouts and subsequent dose-titration periods between the treatment periods. At the end of B, the supine blood pressure (BP) was 156/101, and at the end of B + L and B + C it was 136/91 (p less than 0.001) and 137/91 (p less than 0.0001), respectively, pooling the data from both periods. At the end of B the standing BP was 155/115, and at the end of B + L and B + C 134/100 (p less than 0.001) and 139/106 (p less than 0.0001), respectively. The mean daily doses required were L 476 mg and C 0.335 mg. On a weight basis, labetalol had about 1/1400 of the potency of clonidine. 12 patients complained of tiredness and dry mouth on clonidine and 2 patients of unsteadiness on labetalol. Labetalol caused a psoriasiform rash on the hands in one patient and limb weakness in one patient.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00542319", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "Comparison of labetalol and clonidine in hypertension", 
    "pagination": "363-367", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "35e8ffa5579b74ad4ec977e75a8fdd8c7f578e777fd13a7e6129eb399c0a4b50"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7075640"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "1256165"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00542319"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1011315160"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00542319", 
      "https://app.dimensions.ai/details/publication/pub.1011315160"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130792_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00542319"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00542319'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00542319'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00542319'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00542319'


 

This table displays all metadata directly associated to this object as RDF triples.

170 TRIPLES      21 PREDICATES      57 URIs      31 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00542319 schema:about N0117a4ca490349149a620be93e219036
2 N1862b30a892040679de8d4a13be3a9e3
3 N374d0dfba9e9464faa4e0efbb4e8c81c
4 N4901a91bc5e44abdb6160c37624b8029
5 N4ee5624ff6e34d06867f9cbc7222beca
6 N7da2aee03e714e7a8687989205507c7e
7 N99870e5757a848ba96ce69c8c3f7818c
8 Nb02ffb4950784da5abf9dc601fffa6a7
9 Nf3d0677723cd432fbf00c7553796366e
10 Nf9df1576178a471697d7ada12b8847d5
11 anzsrc-for:11
12 anzsrc-for:1102
13 schema:author N35930fc630b04a989b306ba6448b8d36
14 schema:citation sg:pub.10.1007/bf00605626
15 https://app.dimensions.ai/details/publication/pub.1074688491
16 https://app.dimensions.ai/details/publication/pub.1079782555
17 https://app.dimensions.ai/details/publication/pub.1080041281
18 https://app.dimensions.ai/details/publication/pub.1080271228
19 https://app.dimensions.ai/details/publication/pub.1081648518
20 https://app.dimensions.ai/details/publication/pub.1082562598
21 https://app.dimensions.ai/details/publication/pub.1082562605
22 https://app.dimensions.ai/details/publication/pub.1082562607
23 https://app.dimensions.ai/details/publication/pub.1082562614
24 https://app.dimensions.ai/details/publication/pub.1083377593
25 https://app.dimensions.ai/details/publication/pub.1083377595
26 https://doi.org/10.1001/archinte.1971.00310140061005
27 https://doi.org/10.1042/cs040018pa
28 https://doi.org/10.1055/s-0028-1111588
29 https://doi.org/10.1111/j.1365-2125.1979.tb04771.x
30 https://doi.org/10.1111/j.1365-2125.1979.tb05815.x
31 https://doi.org/10.5694/j.1326-5377.1978.tb112507.x
32 schema:datePublished 1982-09
33 schema:datePublishedReg 1982-09-01
34 schema:description The antihypertensive effect of labetalol (L) was compared with that of clonidine (C) in a randomized cross-over study in 17 hypertensive outpatients on bendrofluazide (B). After treatment for two weeks with B(5 mg qd), either L (100 mg tid) or C (0.1 mg tid) was given and their doses were titrated at 2-weekly visits until normotension was achieve, or intolerable side-effects occurred. The treatment with B and L or C was than continued in a cross-over fashion for two 6-week periods, with 3 week diuretic washouts and subsequent dose-titration periods between the treatment periods. At the end of B, the supine blood pressure (BP) was 156/101, and at the end of B + L and B + C it was 136/91 (p less than 0.001) and 137/91 (p less than 0.0001), respectively, pooling the data from both periods. At the end of B the standing BP was 155/115, and at the end of B + L and B + C 134/100 (p less than 0.001) and 139/106 (p less than 0.0001), respectively. The mean daily doses required were L 476 mg and C 0.335 mg. On a weight basis, labetalol had about 1/1400 of the potency of clonidine. 12 patients complained of tiredness and dry mouth on clonidine and 2 patients of unsteadiness on labetalol. Labetalol caused a psoriasiform rash on the hands in one patient and limb weakness in one patient.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf N3c6b335777c0494e91af0f41bb98c810
39 Nec79d79786b64810bfee8ec39a0ce0dc
40 sg:journal.1054337
41 schema:name Comparison of labetalol and clonidine in hypertension
42 schema:pagination 363-367
43 schema:productId Nb2d0ce64db134425a345b4f324b4c24a
44 Ndfd79294285c4849aa169c8d058dffd2
45 Ne9c13ac6b91a4e52994deae45dc0b3e6
46 Nf259210b4a8e459fa786c3baf2f9f1b6
47 Nfb8898a2cb294bd6b4bddc32531206a0
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011315160
49 https://doi.org/10.1007/bf00542319
50 schema:sdDatePublished 2019-04-11T13:47
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N1bbd5d8b144c4674ade8ff390e853397
53 schema:url http://link.springer.com/10.1007/BF00542319
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N0117a4ca490349149a620be93e219036 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Ethanolamines
59 rdf:type schema:DefinedTerm
60 N1862b30a892040679de8d4a13be3a9e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Clonidine
62 rdf:type schema:DefinedTerm
63 N1bbd5d8b144c4674ade8ff390e853397 schema:name Springer Nature - SN SciGraph project
64 rdf:type schema:Organization
65 N35930fc630b04a989b306ba6448b8d36 rdf:first sg:person.01200755533.60
66 rdf:rest N60aa6c39f0bb4480bfed4edea72746e3
67 N374d0dfba9e9464faa4e0efbb4e8c81c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Labetalol
69 rdf:type schema:DefinedTerm
70 N3c6b335777c0494e91af0f41bb98c810 schema:issueNumber 5
71 rdf:type schema:PublicationIssue
72 N4901a91bc5e44abdb6160c37624b8029 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Hypertension
74 rdf:type schema:DefinedTerm
75 N4ee5624ff6e34d06867f9cbc7222beca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Male
77 rdf:type schema:DefinedTerm
78 N60aa6c39f0bb4480bfed4edea72746e3 rdf:first sg:person.063042215.31
79 rdf:rest Nf4335ad9443943028b437efdda10bd00
80 N7da2aee03e714e7a8687989205507c7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Adult
82 rdf:type schema:DefinedTerm
83 N99870e5757a848ba96ce69c8c3f7818c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Heart Rate
85 rdf:type schema:DefinedTerm
86 Nb02ffb4950784da5abf9dc601fffa6a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Humans
88 rdf:type schema:DefinedTerm
89 Nb2d0ce64db134425a345b4f324b4c24a schema:name nlm_unique_id
90 schema:value 1256165
91 rdf:type schema:PropertyValue
92 Ndfd79294285c4849aa169c8d058dffd2 schema:name pubmed_id
93 schema:value 7075640
94 rdf:type schema:PropertyValue
95 Ne9c13ac6b91a4e52994deae45dc0b3e6 schema:name readcube_id
96 schema:value 35e8ffa5579b74ad4ec977e75a8fdd8c7f578e777fd13a7e6129eb399c0a4b50
97 rdf:type schema:PropertyValue
98 Nec79d79786b64810bfee8ec39a0ce0dc schema:volumeNumber 21
99 rdf:type schema:PublicationVolume
100 Nf259210b4a8e459fa786c3baf2f9f1b6 schema:name doi
101 schema:value 10.1007/bf00542319
102 rdf:type schema:PropertyValue
103 Nf3d0677723cd432fbf00c7553796366e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Middle Aged
105 rdf:type schema:DefinedTerm
106 Nf4335ad9443943028b437efdda10bd00 rdf:first sg:person.01205400765.11
107 rdf:rest rdf:nil
108 Nf9df1576178a471697d7ada12b8847d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Female
110 rdf:type schema:DefinedTerm
111 Nfb8898a2cb294bd6b4bddc32531206a0 schema:name dimensions_id
112 schema:value pub.1011315160
113 rdf:type schema:PropertyValue
114 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical and Health Sciences
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
118 schema:name Cardiorespiratory Medicine and Haematology
119 rdf:type schema:DefinedTerm
120 sg:journal.1054337 schema:issn 0031-6970
121 1432-1041
122 schema:name European Journal of Clinical Pharmacology
123 rdf:type schema:Periodical
124 sg:person.01200755533.60 schema:affiliation https://www.grid.ac/institutes/grid.10858.34
125 schema:familyName Lilja
126 schema:givenName M.
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200755533.60
128 rdf:type schema:Person
129 sg:person.01205400765.11 schema:affiliation https://www.grid.ac/institutes/grid.7737.4
130 schema:familyName Karppanen
131 schema:givenName H.
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205400765.11
133 rdf:type schema:Person
134 sg:person.063042215.31 schema:affiliation https://www.grid.ac/institutes/grid.10858.34
135 schema:familyName Jounela
136 schema:givenName A. J.
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.063042215.31
138 rdf:type schema:Person
139 sg:pub.10.1007/bf00605626 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003306938
140 https://doi.org/10.1007/bf00605626
141 rdf:type schema:CreativeWork
142 https://app.dimensions.ai/details/publication/pub.1074688491 schema:CreativeWork
143 https://app.dimensions.ai/details/publication/pub.1079782555 schema:CreativeWork
144 https://app.dimensions.ai/details/publication/pub.1080041281 schema:CreativeWork
145 https://app.dimensions.ai/details/publication/pub.1080271228 schema:CreativeWork
146 https://app.dimensions.ai/details/publication/pub.1081648518 schema:CreativeWork
147 https://app.dimensions.ai/details/publication/pub.1082562598 schema:CreativeWork
148 https://app.dimensions.ai/details/publication/pub.1082562605 schema:CreativeWork
149 https://app.dimensions.ai/details/publication/pub.1082562607 schema:CreativeWork
150 https://app.dimensions.ai/details/publication/pub.1082562614 schema:CreativeWork
151 https://app.dimensions.ai/details/publication/pub.1083377593 schema:CreativeWork
152 https://app.dimensions.ai/details/publication/pub.1083377595 schema:CreativeWork
153 https://doi.org/10.1001/archinte.1971.00310140061005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050280467
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1042/cs040018pa schema:sameAs https://app.dimensions.ai/details/publication/pub.1043032481
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1055/s-0028-1111588 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057127115
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1111/j.1365-2125.1979.tb04771.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037617622
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1111/j.1365-2125.1979.tb05815.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1014171583
162 rdf:type schema:CreativeWork
163 https://doi.org/10.5694/j.1326-5377.1978.tb112507.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1079782555
164 rdf:type schema:CreativeWork
165 https://www.grid.ac/institutes/grid.10858.34 schema:alternateName University of Oulu
166 schema:name Department of Medicine, University of Oulu, Finland
167 rdf:type schema:Organization
168 https://www.grid.ac/institutes/grid.7737.4 schema:alternateName University of Helsinki
169 schema:name Department of Pharmacology, University of Helsinki, Finland
170 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...